181 related articles for article (PubMed ID: 19208741)
1. Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy.
Horne HN; Lee PS; Murphy SK; Alonso MA; Olson JA; Marks JR
Mol Cancer Res; 2009 Feb; 7(2):199-209. PubMed ID: 19208741
[TBL] [Abstract][Full Text] [Related]
2. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of MAL, a putative tumor suppressor gene, can contribute to human epithelium cell carcinoma.
Cao W; Zhang ZY; Xu Q; Sun Q; Yan M; Zhang J; Zhang P; Han ZG; Chen WT
Mol Cancer; 2010 Nov; 9():296. PubMed ID: 21092172
[TBL] [Abstract][Full Text] [Related]
4. T-lymphocyte maturation-associated protein gene as a candidate metastasis suppressor for head and neck squamous cell carcinomas.
Beder LB; Gunduz M; Hotomi M; Fujihara K; Shimada J; Tamura S; Gunduz E; Fukushima K; Yaykasli K; Grenman R; Shimizu K; Yamanaka N
Cancer Sci; 2009 May; 100(5):873-80. PubMed ID: 19445022
[TBL] [Abstract][Full Text] [Related]
5. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis.
Overmeer RM; Henken FE; Bierkens M; Wilting SM; Timmerman I; Meijer CJ; Snijders PJ; Steenbergen RD
J Pathol; 2009 Nov; 219(3):327-36. PubMed ID: 19662663
[TBL] [Abstract][Full Text] [Related]
6. MAL facilitates the incorporation of exocytic uroplakin-delivering vesicles into the apical membrane of urothelial umbrella cells.
Zhou G; Liang FX; Romih R; Wang Z; Liao Y; Ghiso J; Luque-Garcia JL; Neubert TA; Kreibich G; Alonso MA; Schaeren-Wiemers N; Sun TT
Mol Biol Cell; 2012 Apr; 23(7):1354-66. PubMed ID: 22323295
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic unmasking of epigenetically silenced genes in breast cancer.
Ostrow KL; Park HL; Hoque MO; Kim MS; Liu J; Argani P; Westra W; Van Criekinge W; Sidransky D
Clin Cancer Res; 2009 Feb; 15(4):1184-91. PubMed ID: 19228724
[TBL] [Abstract][Full Text] [Related]
9. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer.
Buffart TE; Overmeer RM; Steenbergen RD; Tijssen M; van Grieken NC; Snijders PJ; Grabsch HI; van de Velde CJ; Carvalho B; Meijer GA
Br J Cancer; 2008 Dec; 99(11):1802-7. PubMed ID: 19002170
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
11. Expression of MAL and MAL2, two elements of the protein machinery for raft-mediated transport, in normal and neoplastic human tissue.
Marazuela M; Alonso MA
Histol Histopathol; 2004 Jul; 19(3):925-33. PubMed ID: 15168355
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylated MAL gene - a silent marker of early colon tumorigenesis.
Lind GE; Ahlquist T; Kolberg M; Berg M; Eknaes M; Alonso MA; Kallioniemi A; Meling GI; Skotheim RI; Rognum TO; Thiis-Evensen E; Lothe RA
J Transl Med; 2008 Mar; 6():13. PubMed ID: 18346269
[TBL] [Abstract][Full Text] [Related]
13. MAL hypermethylation is a tissue-specific event that correlates with MAL mRNA expression in esophageal carcinoma.
Jin Z; Wang L; Zhang Y; Cheng Y; Gao Y; Feng X; Dong M; Cao Z; Chen S; Yu H; Zhao Z; Zhang X; Liu J; Mori Y; Fan X; Meltzer SJ
Sci Rep; 2013 Oct; 3():2838. PubMed ID: 24088706
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer.
Kulak MV; Cyr AR; Woodfield GW; Bogachek M; Spanheimer PM; Li T; Price DH; Domann FE; Weigel RJ
Oncogene; 2013 Aug; 32(34):4043-51. PubMed ID: 22964634
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation-dependent silencing of CST6 in human breast cancer cell lines.
Rivenbark AG; Jones WD; Coleman WB
Lab Invest; 2006 Dec; 86(12):1233-42. PubMed ID: 17043665
[TBL] [Abstract][Full Text] [Related]
16. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma.
Nojima D; Nakajima K; Li LC; Franks J; Ribeiro-Filho L; Ishii N; Dahiya R
Mol Carcinog; 2001 Sep; 32(1):19-27. PubMed ID: 11568972
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of members of glycolipid-enriched membrane raft gene family, MAL and BENE, in cervical squamous cell cancers.
Hatta M; Nagai H; Okino K; Onda M; Yoneyama K; Ohta Y; Nakayama H; Araki T; Emi M
J Obstet Gynaecol Res; 2004 Feb; 30(1):53-8. PubMed ID: 14718022
[TBL] [Abstract][Full Text] [Related]
18. The MAL proteolipid is necessary for the overall apical delivery of membrane proteins in the polarized epithelial Madin-Darby canine kidney and fischer rat thyroid cell lines.
Martín-Belmonte F; Puertollano R; Millán J; Alonso MA
Mol Biol Cell; 2000 Jun; 11(6):2033-45. PubMed ID: 10848627
[TBL] [Abstract][Full Text] [Related]
19. Clustering and lateral concentration of raft lipids by the MAL protein.
Magal LG; Yaffe Y; Shepshelovich J; Aranda JF; de Marco Mdel C; Gaus K; Alonso MA; Hirschberg K
Mol Biol Cell; 2009 Aug; 20(16):3751-62. PubMed ID: 19553470
[TBL] [Abstract][Full Text] [Related]
20. Loss of MAL expression in precancerous lesions of the esophagus.
Mimori K; Nishida K; Nakamura Y; Ieta K; Yoshikawa Y; Sasaki A; Ishii H; Alonso MA; Mori M
Ann Surg Oncol; 2007 May; 14(5):1670-7. PubMed ID: 17151798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
